Monomethyl Auristatin Antibody and Peptide Drug Conjugates for Trimodal Cancer Chemo-Radio-Immunotherapy

Investigators reported therapeutic synergies of targeted cytotoxic auristatin radiosensitization to stimulate anti-tumor immune responses providing a rationale for clinical translational of auristatin antibody drug conjugates with radio-immunotherapy combinations to improve tumor control.